35 results about "TGF beta receptors" patented technology

The invention discloses a method and a composition used for obtaining neuron-like cells from non-neuronal cells via reprogramming. The composition comprises a neuron-like characteristic chemical inducer; the neuron-like characteristic chemical inducer comprises an arbitrary combination of the following ingredients: 1) a cyclic adenosine monophosphate agonist; 2) neurogenic small molecules; 3) glycogen synthase kinase inhibitors, 4) TGF beta receptor inhibitors; 5) BET family bromodomain inhibitors; and 6) a selective inhibitor of Rho-associated, coiled-coil containing protein kinase and / or a p38 mitogen-activated protein kinase inhibitor; wherein 6) is a selective ingredient. The composition used for providing non-neuronal eukaryotic cells with neuron-like characteristics is capable of producing more than 90% TUJ1 positive cells in 16 days of induction. The neuron-like cells obtained via chemical induction possess neuronal specific expression profiles, are capable of generating action potential, and forming functional synapses via further maturation promotion.

Novel hetarylaminoquinoline derivatives of formula (I)wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and / or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and / or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

The present invention is directed to adoptive immunotherapy using a lymphocyte in which an antigen-specific receptor and a bioactive material gene such as an IL-2 gene or a water-soluble TGF-beta receptor gene are transferred. The bioactive material is intensively secreted to, for example, a local site of a tumor, thereby reducing systemic side effects as much as possible, and the survival time of the lymphocyte is increased, thereby further improving the effect of the adoptive immunotherapy.